INTRODUCTION
============

In 2005, deaths attributed to cancer reached 7.5 millions worldwide, and the number of diagnosed cases is postulated to gradually increase and reach about 20 million in 2020 \[[@R1]\]. The battle to combat this deadly disease was initiated in the late 1940\'s with the introduction of the first chemotherapeutic agents. These non-specific agents predominantly affect hyper-proliferating cells, characteristic of many cancers, and exert their cytotoxic effects through different pharmacological modes of action, including induction of DNA damage, inhibition of RNA and DNA synthesis, and/or disruption of the cytoskeleton. The significant contribution to cancer management due to the institution of such chemotherapeutic agents cannot be overestimated. Nonetheless, the overall toxicities and side effects of these drugs limit the dose regime resulting in a narrow therapeutic index and, in most cases the produced responses are insufficient and unpredictable. Furthermore, during the course of therapy, cross-resistance to different chemotherapeutic drugs can be associated with recurrence of the disease \[[@R2]-[@R4]\].

In the late 1980\'s, improved and more specific approaches for treating cancer emerged by virtue of a plethora of chemical and biochemical technologies. One such valid approach involves various strategies that specifically interfere with crucial signaling pathways which are dysregulated in malignant cells and play a pivotal role in the development and maintenance of various cancers. Much effort within this approach has focused on the inhibition of protein tyrosine kinases (PTKs). There are approximately 20 classes of PTKs, including the epidermal growth factor (EGF), insulin, PDGF, FGF, VEGF, and HGF receptor families \[[@R5]\]. The EGF family (receptor tyrosine kinase class I) of membrane receptors, also called human epidermal receptor (HER) family, is one of the most relevant targets in this class. There are four closely related receptors in this family \[[@R6]\]: EGFR (HER1, *erb*B1), HER2 (*neu*, *erb*B2), HER3 (*erb*B3), and HER4 (*erb*B4). Ligands include EGF, amphiregulin, and TGF-α for EGFR, and a group of differentiation factors called neuregulins for HER3 and HER4. Heparin-binding EGF, betacellulin, and epiregulin can stimulate EGFR and HER4. In all cases, ligand binding is followed by formation of receptor homo- or heterodimers. HER2 is unique in that it has no specific ligand and is locked constitutively in a conformation resembling the ligand-bond states. As such, it is subject to heterodimerization with other members of the activated HER family.

EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
=======================================

EGFR (170 kDa) is a membrane-spanning glycoprotein and consists of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular domain with tyrosine kinase activity. Binding of ligand induces the dimerization of receptors, followed by activation of the cytoplasmic tyrosine kinase domain and the subsequent signal transduction cascade. Signal termination occurs mainly by endocytosis of the activated receptor \[[@R7],[@R8]\]. EGFR is associated with oncogenic transformation, and dysregulation of EGFR is associated with all of the key features of cancer \[[@R8]\]. An increased expression of EGFR is the hallmark of many human tumors such as breast cancer, squamous cell carcinoma of the head and neck, and prostate cancer (Table **[1](#T1){ref-type="table"}**).

PTKs AS TARGETS FOR CANCER THERAPY
==================================

PTKs catalyze the transfer of phosphate in ATP to specific tyrosine residues within proteins, thereby altering their structure and function. They play a crucial role in signal transduction pathways that control both intracellular signaling and intercellular communication and are involved in multiple processes such as metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, proliferation, angiogenesis and inhibition of apoptosis. Of the 91 PTKs identified thus far, 59 are receptor TKs, and 32 are cellular TKs, most of them regulating signaling which is crucial for normal cell development and survival. Since PTKs hold a key position in the function of multicellular organisms, it is not surprising that PTK malfunction can lead to conditions such as psoriasis, cardiovascular disease, atherosclerosis and cancer. Most diseases involve PTK dysregulation owing to: a) overexpression of TK receptor and its ligand or both resulting in autocrine-paracrine stimulation; b) dimerization of a PTK receptor or a cellular PTK with a related protein; c) various mutations in the PTK itself, leading to enhanced and sometimes persistent stimulation \[[@R9]-[@R12]\]. Approximately 50% of the known oncogenes encode PTKs \[[@R13],[@R14]\]. As a result, PTKs, whether receptors or cellular proteins have become valid targets to combat cancer through specific biochemical mechanisms meant to decrease side effects \[[@R15]-[@R25]\].

Receptor PTKs can be targeted by two classes of drugs \[[@R26]\]: in the first class, monoclonal antibodies (mAbs) target the extracellular binding domain (Fig. **[1](#F1){ref-type="fig"}**) \[[@R27]\], and inhibit cancer cell growth *via* several direct processes such as interrupting PTK signaling in most cases by blockage of their ligand binding, inhibiting cell cycle progression or DNA repair, reducing angiogenesis, and inducing apoptosis, and *via* indirect processes mediated by the immune system such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) \[[@R26]\] . In the second class, low molecular weight TK inhibitors target the intracellular ATP binding domain of the receptor \[[@R15]\]. Cellular PTKs are exclusively targeted by the latter class of drugs. One of the first PTK mAb inhibitors is the IgG~1~-class monoclonal antibody trastuzumab (Herceptin^®^) (Table **[2](#T2){ref-type="table"}**). Trastuzumab is an anti-erbB2 mAb which increases response rates and improves survival in patients with erbB2-overexpressing breast cancer when combined with conventional chemotherapy \[[@R28],[@R29]\]. It is unique in that, unlike mAbs which target the EGFR, it is only active against cancers that overexpress its target, therefore erbB2 testing prior to treatment is mandatory. Cetuximab is another IgG~1~ class mAb targeting the EGFR (Table **[2](#T2){ref-type="table"}**). Surprisingly, although this mAb displays insufficient effect against EGFR-overexpressing breast cancer, it has yielded positive clinical results against head and neck cancers overexpressing the EGFR and has demonstrated activity in colon cancer regardless of tumor EGFR expression \[[@R30]-[@R32]\]. The mechanisms of action of Cetuximab remain unknown, yet more disturbingly, is the inability to predict patient response. Panitumumab and Matuzumab are other anti-EGFR mAbs (Table **[2](#T2){ref-type="table"}**). Panitumumab has a moderate activity in primary and metastatic colorectal carcinoma with no evident correlation with tumor EGFR expression \[[@R33]-[@R35]\]. The clinical results of Matuzumab in colorectal cancer are suboptimal and the drug is currently undergoing phase II clinical trials for the treatment of lung and stomach cancer. Bevacizumab is an anti VEGF mAb which is used to suppress tumor growth through inhibition of angiogenesis. This drug was approved by the FDA for use in combination with standard chemotherapy in the treatment of metastatic colon cancer and all forms of metastatic non small cell lung cancer. Lately, it was approved by the FDA for the treatment of breast cancer. Although some of the above mentioned mAbs have become accepted drugs in clinical practice, currently there is no reliable clinical modality that would properly select responders and predict therapeutic outcome. However, a correlation between tumor response and skin toxicity has been found which may indicate that some patients not responding to treatment were \"underdosed\" \[[@R36],[@R37]\].

The second class of compounds is low molecular weight TK inhibitors which target the ATP binding domain of PTKs and disrupt the hyperactive signal transduction pathways in cancer cells. The first step in the development of low molecular weight PTK inhibitors began shortly following the recognition in the early 1980\'s that natural compounds such as quercetin, genistein, lavendustin, erbstatin and herbimycin A \[[@R38]-[@R43]\] are potent inhibitors of PTKs. Although these natural compounds have no selectivity and therefore were found to be very toxic, they served as starting templates for the design and development of synthetic, more potent and selective PTK inhibitors. The benzylidine moiety of erbstatin and other arylidene derivatives were developed into a class of PTK blockers defined as tyrphostins (tyrosine phosphorilation). The first group of PTK inhibitors synthesized was the benzene malononitrile tyrphostins \[[@R44]-[@R47]\]. These compounds were competitive with the substrate and non competitive with ATP. In the mid-1990\'s, when structure activity led to bicyclic tyrphostins, the main thrust in the development of PTK inhibitors was to endorse a generation of ATP competitive kinase inhibitors. The most common chemical structures of these tyrphostins are anilinoquinazolines, anilinoquinolines and anilinopyridopirimidines.

Although ATP binding sites are highly conserved among tyrosine kinases, minor differences in kinase domain structures in combination with combinatorial chemistry, structured-based drug design and computational chemistry have led to the development of highly selective PTK inhibitors. In the past few years, over 30 inhibitors were at various stages of development. Clinical studies conducted recently have recognized some of these inhibitors as therapeutic drugs for specific cancers. Imatinib (STI-571;Gleevec) (Table **[2](#T2){ref-type="table"}**, Fig. **[2](#F2){ref-type="fig"}**) has been identified as an effective Bcr-Abl inhibitor with durable response in patients in the early phase of chronic myelogenous leukemia (CML) with minimal side effects \[[@R48],[@R49]\]. Imatinib is also the standard of care, first-line treatment for unresectable or metastatic gastrointestinal stromal tumors \[GIST\] \[[@R50]\], especially in patients who harbor activating mutations in c-Kit.

In the field of cancer angiogenesis, various VEGFR inhibitors are currently being evaluated in clinical trials, including semaxanib and vatalanib (Table **[2](#T2){ref-type="table"}**, Fig. **[2](#F2){ref-type="fig"}**). In clinical studies, vatalanib, which inhibits VEGFR-1 and -2, PDGFR and c-Kit, has been shown to suppress hepatocellular carcinoma (HCC) growth and to have anti-neoplastic effects in other solid tumors \[[@R51],[@R52]\]. Sunitinib (Sutent, Table **[2](#T2){ref-type="table"}**), another promising agent against angiogenesis, inhibits the VEGFR as well as the PDGFR, c-KIT and Flt3 tyrosine kinases. Sunitinib has been approved for the treatment of renal cell carcinoma and for the treatment of GIST, and is currently tested in phase II trials for HCC \[[@R53],[@R54]\]. Most of these drugs produce limited response as monotherapeutic agents against solid tumors and are considered to be more effective in combination with other PTK drugs \[[@R55]-[@R59]\].

Three EGFR/erbB2 low molecular weight reversible inhibitors have thus far been approved for clinical use: lapatinib, gefitinib and erlotinib (Table **[2](#T2){ref-type="table"}**, Fig. **[2](#F2){ref-type="fig"}**), and numerous other drug candidates are in various stages of development. Gefitinib and erlotinib are more selective for the EGFR, while lapatinib targets both EGFR and erbB2. Promising results have been obtained using gefitinib and erlotinib in pre-clinical models of EGFR overexpressing cell lines and xenografts \[[@R60],[@R61]\]. Nonetheless, these results failed to reproduce in the clinical setting since both agents appear to be effective only in the subset of NSCLC patients \[[@R62]\]. Higher response rates to gefitinib and erlotinib therapies have also been reported in patients with EGFR expressing tumors containing well-defined activating mutations \[[@R63]-[@R67]\]. This higher sensitivity of the mutant form could be due to structural changes at the kinase domain mutation rendering the receptor more receptive to inhibitor binding. However, similarly to imatinib, patients who initially responded to these treatments have occasionally developed therapy resistance due to acquired secondary mutation in the EGFR \[[@R68]\], thus, necessitating the acquisition of further clinical and experimental data so as to better predict response to such therapies. More recent pre-clinical and clinical publications indicate that irreversible inhibitors of the EGFR such as Canertinib and EKB-569 (Fig. **[2](#F2){ref-type="fig"}**, Table **[2](#T2){ref-type="table"}**) appear to circumvent this resistance suggesting that this category of inhibitors may benefit from a larger clinical application \[[@R68]-[@R72]\].

The concept of targeted therapies by specifically inhibiting PTKs in cancer is very promising, albeit several drugs that have entered clinical trials have not yielded the predicted positive outcome. This inconsistency can be attributed to several factors working in unison or independently of each other including: inappropriate selection of potential responders in terms of the expression of the targeted protein in a particular tumor; insufficient inhibition of the targeted PTKs due to inappropriate dosage schedule; resistance due to a secondary mutation in the PTKs developed during therapy; loss of the survival factor role of the targeted PTKs in cancer cells during therapy, and the development of other pathways as a salvage and escape mechanism for cancer cell survival. One possible approach that may yield better results would be either to use multi-drug therapies working in synergy and meant to target several PTKs \[[@R15],[@R73]\], or drugs targeting multiple PTKs which play a major role in cancer cell proliferation. Better yet, a reliable and accurate quantitative assay to determine PTK levels and their role in tumors is required to establish a customized targeted treatment \[[@R74]\].

NUCLEAR MEDICINE AND PET MOLECULAR IMAGING OF EGFR
==================================================

As tumor cells are characterized by uncontrolled proliferation and enhanced cell growth, it has been observed that most tumor cells over-express one or several hormone receptors \[[@R75]\]. Radiopharmaceuticals which selectively target those receptors can be used to diagnose and/or treat cancer. Molecular imaging of tumors *via* nuclear medicine modalities such as single photon computed tomography (SPECT) or positron emission tomography (PET) using targeted radiopharmaceuticals, could visualize the underlying mechanism of cellular processes *in vivo* and complements and enhances anatomical information acquired by computed tomography (CT) and magnetic resonance imaging (MRI). PET is based on the administration of radioactively-labeled probes (radiopharmaceutical) with characteristic physiological or biological properties. Following the administration of the probe, spatial and temporal monitoring of its biodistribution within the body is conducted using a PET scanner. To this end, the desired molecule (either natural or synthetic) is labeled with a positron-emitting isotope. Positrons (*β^+^)*travel only a few millimeters before they encounter an electron, which leads to the formation of two annihilation photons at a 180° angle. Simultaneous detection of these two 511 keV photons by the scanner forms the basis of PET imaging. The resolution of clinical PET scanners is in the low millimeter range, which is not as high as MRI (100--500 μm), but higher than that of the alternative method SPECT (3--6 mm). However modern PET/ CT scanners offer a more accurate anatomic localization of radioactivity, thereby enhancing the interpretation of PET images. The superiority of nuclear medicine compared to other imaging modalities stems from its high sensitivity, in a nanomolar (nM) concentration-range, as opposed to millimolar (mM) concentrations for other related imaging techniques, thus enabling *in vivo* quantitative visualization of \"low capacity systems\" such as receptors and enzymes. After a tumor is diagnosed, a targeted radiopharmaceutical can be used to determine the optimal therapy by identifying key molecular markers on the tumor cells. During the course of therapy, the radiopharmaceutical can be used to monitor early response to the chosen targeted treatment.

Immunohistochemistry (IHC) is the most frequently applied method for evaluating PTK expression in tumor tissues, however, it requires tissue biopsies, which are not always available and furthermore, do not always represent the pathology of the whole tumor nor of distant, unexamined metastases. Additionally, IHC provides only semi-quantitative data, and can be inconsistent due to variations in methodology \[[@R76]\]. Thus, many hurdles remain to be overcome in order to effectively treat various types of cancers by targeted PTK therapy. Molecular imaging such as PET coupled with suitable selective labeled bioprobes that target specific PTKs has the potential to resolve some of the above mentioned obstacles by: 1) noninvasively determining whether the target protein is expressed in a specific tumor and its metastasis; 2) monitoring target-drug binding and receptor occupancy *in vivo*; 3) determining duration of PTK inhibition *in vivo*; and 4) potentially identifying the existence of a primary or secondary mutation leading to either drug interaction or loss of PTK recognition by the drug.

As demonstrated above, EGFR expression in tumors is not sufficient to predict EGFR targeted therapeutic response. However, in many cases, its overexpression in tumors is a prerequisite for initiating such treatment and can be measured non-invasively by molecular imaging modalities such as PET. Indeed, within the PTKs, most research has primarily focused on EGFR as a target for PET imaging either by the development and acquisition of labeled monoclonal antibodies directed to the extracellular binding domain or by the development of low molecular weight PET agents derived from the anilinoquinazoline skeleton of existing or potential drugs targeting the intracellular ATP binding domain of the receptor \[[@R77]\].

RADIOPHARMACEUTICALS FOR IMAGING EGFR EXPRESSION IN TUMORS
==========================================================

Radiolabeled Intact mAbs for Imaging EGFR Expression in Tumors
--------------------------------------------------------------

The use of radiolabeled anti-EGFR antibodies for EGFR-expressing cancer diagnosis has become the subject of intense investigation as more mAbs with relevant and well-characterized specificities become available. Anti-EGFR mAbs have been used and evaluated for imaging with a variety of radionuclides, including radiometals and radiohalogens (Table **[3](#T3){ref-type="table"}**). Cetuximab attached to the radiometal chelator diethylenetriaminepentaacetic acid (DTPA) and labeled with ^111^In was shown to localize specifically in tumors that over-express EGFR \[[@R78],[@R79]\]. However, a considerable amount of radioactivity in the liver was observed limiting the clinical usefulness of this agent for cancer imaging. An improved cetuximab conjugate (DTPA-PEG-cetuximab) was reported to overcome this problem, as tumor imaging of ^111^In-DTPA-PEG-cetuximab in nude mice showed significant reduction of radioactivity in the liver using a gamma camera \[[@R79]\]. Although cetuximab Fab\' and F(ab\')~2~ fragments have been investigated, they have reduced binding affinity (5-fold weaker) and showed less inhibition of tumor growth than the intact antibody \[[@R80]\].

Perk *et al.*, reported the biodistribution of positron-emitting ^89^Zr-deferrioxamine-cetuximab as a surrogate imaging agent for therapy with ^90^Y and/or ^177^Lu-DOTA-cetuximab \[[@R81]\]. Cetuximab-*N*-sucDf-^89^Zr showed very comparable tumor uptake and clearance in non-target tissues to cetuximab-*p*-SCN-Bz-DTPA-^88^Y (where gamma-emitting ^88^Y was used for biodistribution studies) and cetuximab-*p*-SCN-Bz-DTPA-^177^Lu. The only difference in biodistribution was a higher uptake of cetuximab-*N*-sucDf-^89^Zr in the bone, compared to the ^88^Y and ^177^Lu-labeled agents.

Cai *et al.*, reported the biodistribution of ^64^Cu-DOTA-cetuximab (Fig. **[3](#F3){ref-type="fig"}**) in seven different EGFR-expressing tumor-bearing mouse models \[[@R82]\]. A correlation between EGFR expression by Western blot analysis and %ID/g in the various tumor types was observed, suggesting that ^64^Cu-DOTA-cetuximab is a potentially accurate biomarker for EGFR expression. In another study, Li*et al.* showed high uptake of ^64^Cu-DOTA-cetuximab in A431 tumors, although there was significant uptake in the liver, in part due to ^64^Cu dissociation from the DOTA chelator \[[@R83]\]. Improved chelation systems for labeling ^64^Cu to cetuximab will greatly improve this agent for future human PET imaging studies.

Radiolabeled Affibodies for Imaging EGFR Expression
---------------------------------------------------

Smaller molecular weight "affibodies" that bind to EGFR have been developed as alternatives to radiolabeled intact mAbs as imaging agents. Affibody molecules are three-helix bundle molecules based on 58 amino acids and are derived from the IgG-binding domains of staphylococcal protein A \[[@R84]\]. (Z~EGFR:\ 955~)~2~, a 14.6 kDa molecule, was selected from a phage display library consisting of 13 randomized residues, and binds to EGFR on cultured cells with low nanomolar affinity \[[@R85]\]. The smaller size compared to intact antibodies (\~150 kDa) will allow greater tumor penetration and more rapid blood clearance.

The Affibody (Z~EGFR:\ 955~)~2~ was labeled with ^125^I and compared to ^125^I-labeled EGF and cetuximab \[[@R84]\]. In A431 cells grown in culture, the uptake of ^125^I-labeled (Z~EGFR:\ 955~)~2~ was more rapid than that of the other agents, and was found to be cell-associated for a longer time period, suggesting more rapid internalization and greater retention in EGFR-positive tumor cells. Affibody (Z~EGFR:\ 955~)~2~ was also labeled with ^111^In, and in A431 tumor-bearing mice showed high tumor uptake, with tumor: blood ratios of 9.1 at 4 h post-injection \[[@R86]\].

Additional Affibody molecules were developed through the affinity maturation process and radiolabeled with ^111^In \[[@R87]\] for evaluation in A431 tumor-bearing mice. All agents evaluated in tumor-bearing mice showed tumor uptake between 5-7% ID/g at 4 h post-injection with tumor: blood ratios of \~3. The kidney uptake was extremely high, however, with uptake ranging between 100-200 %ID/g.

Low Molecular Weight Imaging Agents
-----------------------------------

Attempts to develop low-molecular weight imaging agents that target the TK domain of the EGFR have been mainly focused on the 4-anilinoquinazoline class of compounds that has been originally developed for therapy. The reversible inhibitor PD 153035 was one of the first templates used for developing such molecular imaging agents. It was labeled with carbon-11 at the 7-methoxy position of the quinazoline ring (Fig. **[4](#F4){ref-type="fig"}**) and its biodistribution properties and specific uptake in the examined tissues have been investigated in non-tumor bearing mice \[[@R88]\]. Specific binding in these blocking studies by pre-administration of an excess of unlabeled PD153035 could not be demonstrated and an increase (rather than a reduction) in the levels of activity uptake in tissues was obtained \[[@R88]\]. In another study, PD153035 was non-specifically labeled either at the 6- or 7-methoxy positions and its biodistribution using PET in rats bearing EGFR-rich SH-SY5Y human neuroblastoma xenografts, revealed a low maximum tumor activity-uptake value of \~0.3% injected tracer dose per mL of tumor tissue (%ID/mL) at less than 10 min post injection \[[@R89]\]. At this time period, radioactivity uptakes in the gastrointestinal (GI) tract and in the liver were about 2 to 2.5-fold higher, resulting in high activity background levels. Moreover, specific tumor uptake was not confirmed in a blocking study. Derivatives of PD 153035 were labeled with ^123^I (t~1/2~ = 13.3 h), ^125^I (t~1/2~ = 59.4 d) and ^18^F (t~1/2~ = 110 min.) (Fig. **[4](#F4){ref-type="fig"}**); however, specific binding of the labeled compounds to the EGFR was demonstrated only *in vitro* using EGFR positive MDA-MB 468 human breast cancer cells \[[@R90]\]. In a later report, the biodistribution of ^123^I-PD153035 analog was evaluated by a dynamic gamma camera scan in rats bearing subcutaneous xenografts of 13762 MAT rat mammary adenocarcinoma cells \[[@R91]\]. Although it remains unclear whether this cell line expresses the EGFR, maximal tumor activity uptake was obtained between 30 and 60 min post injection of the tracer, followed by a decrease to background tissue levels after 5 h. Quantification of the data was neither performed, nor was there any specific binding demonstrated in this study.

A radiosynthetic strategy has been developed for fluorine-18 labelling of 6,7-disubstituted 4-anilinoquinazolines at the anilino moiety \[[@R92]-[@R94]\]. In general, it was based on the nucleophilic substitution of the nitro group of dinitrobenzene derivatives with fluorine-18, followed by reduction of the second nitro group to yield labeled aniline. Subsequently, the \[^18^F\]-labeled aniline was coupled to the 6,7- disubstituted 4\'-chloroquinazoline moiety to furnish the final fluorine-18 labeled compounds. This methodology was used for the formation of several potential fluorine-18 labeled PET probes, derived from therapeutic agents such as erlotinib, gefitinib and ZD6474. \[^18^F\]ML01 (Fig. **[4](#F4){ref-type="fig"}**) was one of the most studied compounds among these reversible labeled inhibitors. Its median inhibitory concentration (IC~50~) values in an enzyme-linked immunosorbent assay (ELISA), using A431-derived cell membranes that overexpress the receptor, and in intact A431 cells were 0.2 nM and 3.8 nM, respectively. \[^18^F\]-ML01 exhibited high specific binding and could accurately measure receptor content (B~max~) in intact A431 cells. In a study testing the kinetics of ML01 binding to EGFR, the association and dissociation-rate constants (K~on~, K~off~) were obtained, and a derived k~D~ value of 65 nM, defined as K~off~/K~on~, was calculated. According to the number of EGFR binding-sites per A431 cell \[[@R95]-[@R97]\], and assuming 10^9^ cells per gram of tumor, an estimated B~max~ value of 200 nM EGFR in the tumor tissue could be obtained, yielding a rather low binding potential (BP) of \~3. This could explain why although ML01 exhibited significant inhibitory potency and adequate specific binding to the receptor *in vitro*, its*in vivo* performance was less promising. Indeed, PET-imaging of A431 tumor-bearing mice following I.V. administration of \[^18^F\]-ML01 indicated that although tumor could be clearly detected, its visualization persisted for a narrow imaging time-frame of 8-12 min post injection. Thus, kinetic factors such as rapid dissociation from the receptor and elevated blood clearance rendered ML01 ineffective as a tracer for imaging the EGFR \[[@R94]\].

Gefitinib was labeled with fluorine-18 in a similar fashion to ML01 \[[@R92]\]. In addition, the radiolabeling of gefitinib with carbon-11 at the C-7 methoxy group has also been reported (Fig. **[4](#F4){ref-type="fig"}**) \[[@R98]\]. The first biological evaluation performed with radiolabeled gefitinib was presented in 2003. The potential of the fluorine-18 labeled compound as an imaging agent was investigated by microPET studies; however, neither significant tumor uptake nor specific binding could be demonstrated \[[@R99]\]. These findings were supported by a recent and more detailed report \[[@R100]\] in which the microPET study did not show preferential activity uptake in tumors relative to surrounding skeletal muscle; furthermore, in all studied tumor types, the tumor: blood activity uptake ratio was \< 1 during 2 h post injection of the tracer, and the obtained binding potential (BP) was similar in EGFR positive and negative xenografts.

Although the above described labeled compounds are either identical to or derivatives of existing drugs, they have not yielded promising target-specific agents for PET tumor imaging since more prerequisites have to be fulfilled. It is of utmost importance that a tracer level administration of the imaging agent (as opposed to drug which can be administered up to the maximum tolerated dose) furnishes high and specific accumulation in the target tissue. This tumor uptake should be significantly higher than in the surrounding tissue to yield elevated signal: noise ratio which is mandatory for imaging. Thus, favorable pharmacokinetics and minimum levels of radiolabeled metabolites are equally required for adequate imaging. Up till now, anilinoquinazoline-based radiolabeled reversible inhibitors, although generally exhibiting high potential as imaging agents *in vitro*, they have not yielded adequate PET imaging of EGFR-overexpressing tumors in an animal model. This failure could be attributed to their elevated log P, fast blood clearance, rapid metabolism, and binding competition between manifold higher levels of intracellular ATP and the radioligand resulting in the rapid washout of the labeled inhibitor from the tumor. Subsequently, attempts have been made for the development of irreversible inhibitors of the EGFR as potential imaging agents (Fig. **[4](#F4){ref-type="fig"}**) \[[@R101]-[@R111]\]. Out of the numerous developed labeled irreversible EGFR inhibitors, four were intensely studied as imaging agent candidates, i.e., \[^11^C\]-ML03, \[^11^C\] and \[^18^F\]-ML04, \[^18^F\]-FEQA and morpholino \[^124^I\]-IPQA. In this category of irreversible EGFR PET agent candidates, the carbon-11 labeled 6-acrylamido-4-(3,4-dichloro-6-fluoroanilino) quinazoline, ML03, (Fig. **[4](#F4){ref-type="fig"}**) was the first to be synthesized and labeled \[[@R101],[@R103]\]. ML03 exhibited a remarkable inhibitory potency with an IC~50~ of 0.037 nM in a cell-free assay combined with sustained inhibition of the receptor in intact A431 cells; its specific binding to the receptor was demonstrated in a cell binding assay and also in tissue sections of liver and A431 tumors. However, its fast degradation *in vivo* in combination with low tumor activity uptake levels along with pronounced activity concentration in the liver, kidney and intestine, obtained in tumor-bearing rat biodistribution studies, rendered \[^11^C\]-ML03 ineffective as a tracer for imaging of the EGFR \[[@R99]\]. In 2003, the preparation and biological evaluation of an additional labeled acrylamido-anilinoquinazoline derivative, N-{4-\[3\'-\[^18^F\]fluoroethylphenyl)amino\]-6-quinazolinyl}acrylamide (\[^18^F\]-FEQA) was reported \[[@R112]\]. A dynamic microPET scan was performed in A431 tumor-bearing mice in order to study tracer biodistribution. A rather low maximal tumor: blood activity uptake ratio of 0.12 was obtained shortly post administration of the tracer, which decreased over time. In contrast, a high activity uptake in metabolic and excretory organs was detected as inferred by the relatively high tissue: blood activity uptake ratio that was obtained at further time points in the gallbladder and bladder, indicating rapid clearance of the labeled compound probably *via* both renal and hepatobiliary routes. Thus, although the tumor could be visualized, high levels of background activity were observed, and more importantly, the EGFR specific tumor uptake was not evaluated. Another interesting EGFR-TK PET agent is the (E)-But-2-enedioic acid \[4-(3-\[^124^I\]iodoanilino)-quinazolin-6-yl\]-amide-(3-morpholin-4-yl-propyl)-amide (morpholino-\[^124^I\]-IPQA) (Fig. **[4](#F4){ref-type="fig"}**) \[[@R110]\]. It has a unique potential as a PET agent since it has shown for the first time selective and irreversible binding to the ATP-binding site of the activated (phosphorylated), but not to the inactivated EGFR kinase, thus having the ability to discriminate *in vivo* between these two forms of the receptor. In dynamic PET scans of rats bearing two xenografts, a gradual accumulation of the tracer in A431 (EGFR-positive), but not in human chronic myeloid leukemia K562 (EGFR-negative) tumors, was observed. However, only a moderate activity uptake value in the positive xenograft of \~0.72 a% id/ g tumor, at 1 h post injection of the tracer was obtained. Although this approach indicates, to some extent, specific uptake, more convincing evidence such as direct *in vivo* blocking studies would be required. The major drawbacks of morpholino-\[^124^I\]-IPQA include low solubility, significant hepatobiliary clearance, and intestinal reuptake.

Major progress with irreversible PET EGFR biomarkers has been achieved with the development of ML04 \[[@R109]\]. It demonstrated potent, irreversible inhibition of the EGFR in four human cell lines that express this receptor (Table **[4](#T4){ref-type="table"}**). The comparable inhibition levels obtained both immediately after and 8 h after removal of the inhibitor from the medium suggest that ML04 binds to the EGFR covalently and indeed inhibits activation of the receptor in an irreversible manner. This cell-based assay was originally introduced by Fry and colleagues as an additional supporting indicator of irreversible bonding \[[@R113]\]; later, this methodology has been routinely used as a reliable criterion of irreversible inhibition \[106, 114, 115\]. In addition, ML04 was found to selectively bind to the EGFR with a 250-fold inhibitory potency compared to other closely related tyrosine kinases with the exception of erbB2 which shares 80% homology with EGFR in its kinase domain (Table **[4](#T4){ref-type="table"}**). Following injection of the compound to U87MG.wt EGFR tumor-bearing mice (5 mg/kg i.v.), ML04 demonstrated significant inhibition of EGFR phosphorylation levels in tumors *in vivo* at different time points post administration. As indicated in Fig. (**[5](#F5){ref-type="fig"}**), significant inhibition of phosphorylation persisted for at least 6 h post administration of the inhibitor indicating that, indeed, the compound reached the tumor and penetrated the cancer cells in sufficient quantity so as to bind to a relatively significant portion of the receptors for an extended period of time, as expected from irreversible inhibitors. The compound was successfully labeled either with carbon-11 on the dimethylamine moiety *via* C-11 methylation reaction using C-11 methyl iodide \[[@R105]\] or with fluorine-18 at the anilino moiety *via* a multistep radiosynthesis route \[108\]. In binding studies employing fluorine-18 ML04 and A431 cells, the compound demonstrated high specific binding of approximately 75% and could accurately measure the number of EGFR molecules per cell. In addition and in contrast to ML03, the previously labeled irreversible inhibitor, ML04 was found to be stable in blood either in ex vivo or *in vivo* studies. *In vivo* biodistribution of the radiolabeled compound revealed higher activity uptake in EGFR-positive tumors as compared to previously studied EGFR PET imaging agent candidates, and a remarkable tumor: blood and tumor: muscle activity uptake ratios of about 7 and 5, respectively, three hours following administration of the radiotracer (Table **[5](#T5){ref-type="table"}**). Nevertheless, only minor EGFR specific uptake of the compound was detected *in vivo* using EGFR-negative tumors or blocking studies as controls (Fig. **[6](#F6){ref-type="fig"}**) \[[@R109]\]. A possible explanation of this observation could stem from the relatively high log P of ML04 which on the one hand, is required for cell penetration, while, on the other, it leads to high accumulation of the compound in the extracellular space of the tumor, resulting in high non-specific uptake. Therefore, derivatives of the compound such as ML09 \[[@R111]\], ML10 and ML11 (Fig. **[4](#F4){ref-type="fig"}**) which exhibit lower log P, yet not too low to enable cell penetration, have been developed and labeled with fluorine-18 *via* one step radiosynthesis, Iodine-124 or carbon-11 (Scheme **[1](#S1){ref-type="scheme"}**) and are currently under investigation (unpublished results).

SUMMARY
=======

In conclusion, the EGFR has been recognized as one of the most promising targets for the treatment of cancer. Indeed, several drugs, either based on monoclonal antibodies targeting the extracellular domain of the receptor or small organic molecules targeting the tyrosine kinase domain, are FDA-approved and many others are in various stages of development. However, the therapeutic potential of targeting the EGFR remains to be refined and optimized. Quantitative PET molecular imaging, coupled with selective labeled biomarkers, may facilitate *in vivo* EGFR-targeted drug efficacy by noninvasively assessing expression of EGFR in tumor, guiding dose and regime by measuring target-drug binding, receptor occupancy, and duration of inhibition, as well as potentially detecting the existence of a primary or secondary mutation leading to either drug interaction or failure of EGFR recognition by the drug. Two approaches have been undertaken for the development of EGFR PET imaging agents: labeling monoclonal antibodies and small organic molecules. These labeled compounds were based on either approved or drugs in the process of development. In the case of labeled monoclonal antibodies, Cetuximab has provided the most encouraging results by exhibiting high specificity and high accumulation in tumor, however, its slow clearance from the bloodstream and metabolic tissues results in limited imaging contrast at early time points post injection. Therefore, the labeling of smaller antibody fragments may emerge in the near future. In the case of small organic molecules, the main hurdles to be overcome include excessive clearance from blood, nonspecific binding and inadequate pharmacokinetic properties. Even though some of these developed imaging agents were based on approved drugs, they did not yield adequate PET imaging. Based on these findings, it is evident that the properties of successful targeted drugs will not always lead to efficient tracer level imaging agents. Indeed, important features should be taken into consideration when designing optimal imaging agents including, affinity, selectivity, stability, suitable Log p, optimal blood clearance, low uptake in non target tissues, and high specific binding in target tissues. Future trends in this investigation will probably focus on the development of labeled EGFR affibodies targeting the extracellular domain and labeled small organic molecules directed toward the intracellular substrate binding site rather than the ATP binding site.

C225

:   = Cetuximab

CML

:   = Chronic myelogenous leukemia

CT

:   = Computed tomography

DOTA

:   = 1,4,7,10- Tetraazacyclododecane-1,4,7,10-tetraacetic acid

DTPA

:   = Diethylenetriaminepentaacetic acid

ELISA

:   = Enzyme-linked immunosorbent assay

EGF

:   = Epidermal growth factor

EGFR

:   = Epidermal growth factor receptor

EOB

:   = End of bombardment

GIST

:   = Gastrointestinal stromal tumors

HCC

:   = Hepatocellular carcinoma

HER 2, 3, 4

:   = Human EGFR 2, 3, 4

IC~50~

:   = Median inhibitory concentration

%ID/g

:   = Percentage of the injected dose measured per gram of tissue or organ

IHC

:   = Immunohistochemistry

mM

:   = Millimolar

MRI

:   = Magnetic resonance imaging

nM

:   = Nanomolar

NSCLC

:   = Non small cell lung cancer

PDGFR

:   = Platelet-derived growth factor receptors

PET

:   = Positron emission tomography

PTKs

:   = Protein tyrosine kinases

PY

:   = Phosphotyrosine

RTK

:   = Receptor tyrosine kinase

SCCHN

:   = Small cell carcinoma of the head and neck

SPECT

:   = Single-photon emission computed tomography

TK

:   = Tyrosine kinase

VEGFR

:   = Vascular endothelial growth factor receptor

![Mechanism of action of anti-EGFR mAb-based drugs.](CPD-14-2983_F1){#F1}
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![Preparation of ^64^Cu-DOTA-cetuximab for PET imaging of EGFR-positive tumors.](CPD-14-2983_F3){#F3}
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![*In vivo* inhibition of phosphorylation of the EGFR in U87MG.wt EGFR xenografts is attained after administration of an excess of ML04 to mice.](CPD-14-2983_F5){#F5}

![Preferential uptake of \[18F\]-ML04 in U87MG.wt EGFR over U138MG tumors.](CPD-14-2983_F6){#F6}

![Labelling of ML09, ML10 and ML11.](CPD-14-2983_S1){#S1}

###### 

EGFR Expression in Solid Tumors \[[@R6], [@R116]\]

  Tumor Type      Range of Tumors Expressing EGFR (%)   Tumor Type     Range of Tumors Expressing EGFR (%)
  --------------- ------------------------------------- -------------- -------------------------------------
  Head and neck   80--100                               Prostate       40--80
  Colorectal      25--77                                Bladder        53--72
  Pancreatic      30--50                                Cervical       54--74
  Lung            40--80                                Ovarian        35--70
  Esophageal      71--88                                Breast         14--91
  Renal cell      50--90                                Glioblastoma   40--50

###### 

Protein Tyrosine Kinases (PTKs) Targeted Drugs

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Drug/*Type*                              PTKs                      Indication
  ---------------------------------------- ------------------------- ----------------------------------------------------------------------------
  Cetuximab (Erbitux)/ *mAb*               erbB1 (EGFR)              colorectal cancer, phase III for head/neck, pancreatic\
                                                                     cancers and NSCLC, Phase II for HCC

  Matuzumab (EMD 72000)/*mAb*              erbB1 (EGFR)              phase I/II for NSCLC, ovarian, pancreatic cancer

  Panitumumab (ABX-EGF, Vectibix )/*mAb*   erbB1 (EGFR)              colorectal cancer, phase I for refractory solid Tumors

  Erlotinib (Tarceva)*TK inhibitor*        erbB1 (EGFR)              NSCLC, pancreatic cancer, phase II for HCC

  Gefitinib (Iressa)/*TK inhibitor*        erbB1 (EGFR)              NSCLC, phase I for HCC

  EKB-569/*TK inhibitor*                   erbB1 (EGFR)              phase II for advanced colorectal cancer and NSCLC

  Lapatinib (Tykerb)/*TK inhibitor*        erbB1 (EGFR)/ erbB2       advanced metastatic breast cancer

  Canertinib (CI-1033)*/TK inhibitor*      Pan-erbB                  phase II for SCC, ovarian and metastatic breast cancer cancer

  Trastuzumab (Herceptin)/*mAb*            erbB2                     Breast cancer

  Imatinib (Gleevec)/*TK inhibitor*        ABL, PGRFR, KIT           CML, CMML, CEL, GIST

  Bevacizumab (Avastin)\*/*mAb*            VEGF A                    NSCLC, colorectal cancer

  Semaxanib (SU5416)/*TK inhibitor*        VEGFR, EGFR, KIT          phase II for metastatic melanoma

  Sunitinib (Sutent)/ *TK inhibitor*       VEGFR, KIT, PDGFR, Flt3   GIST, Renal cell carcinoma

  Vatalanib/ *TK inhibitor*                VEGFR, PDGFR              phase III for colorectal and phase II for GIST, prostate and kidney cancer
  -----------------------------------------------------------------------------------------------------------------------------------------------

**NSCLC**, non small cell lung cancer; **HCC**, hepatocellular cancer; **CML**, Chronic myeloid leukemia; **CMML**, Chronic myelomonocytic leukemia; **CEL**, Chroniceosinophilic leukemia; **GIST**, Gastrointestinal stromal tumor; **SCC**, Squamous cell carcinoma.

###### 

Decay Characteristics of Radionuclides Used to Label Anti-EGFR mAbs

  ----------------------------------------------------------------------------
  Isotope   T~1/2~   β ^-^MeV (max) (%)   β ^+^MeV (max) (%)   γ MeV (%)
  --------- -------- -------------------- -------------------- ---------------
  ^64^Cu    12.7 h   0.573 (39.6%)        0.655 (17.4%)        0.51 (34.8%)

  ^88^Y     108 d    \-                   \-                   0.898 (91%)\
                                                               1.836 (100%)

  ^89^Zr    78.4 h   \-                   0.9 (22%)            0.511 (44%)\
                                                               0.91 (99%)\
                                                               1.71 (1%)

  ^111^In   67.4 h   \-                   \-                   0.173 (89%)\
                                                               0.247 (94%)

  ^125^I    60.2 d   \-                   \-                   0.035 (7%)

  ^177^Lu   6.74 d   0.497 (90%)\         \-                   0.113 (2.8%)\
                     0.385 (3%)                                0.208 (6.1%)
  ----------------------------------------------------------------------------

###### 

ML04 is a Potent, Irreversible and Selective Inhibitor of the EGFR

  Investigated Tyrosine Kinase (Cell Line)   IC~50~ Values in Intact Cells \[nM\] [a](#TFN1){ref-type="table-fn"}   IC~50~ Values in a Cell-Free Kinase Assay \[nM\] [a](#TFN1){ref-type="table-fn"}   
  ------------------------------------------ ---------------------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------
  EGFR (A431)                                4-10 [b](#TFN2){ref-type="table-fn"}                                   10-50 [b](#TFN2){ref-type="table-fn"}                                              0.11 ± 0.08 [b](#TFN2){ref-type="table-fn"}
  EGFR (MDA-MB 468)                          1-5                                                                    1-5                                                                                
  EGFR (PC10)                                10-50                                                                  10-50                                                                              
  EGFR (NCI-H1975)                           25                                                                     ND                                                                                 
  EGFR (DHER14)                              4 [b](#TFN2){ref-type="table-fn"}                                      ND                                                                                 
  HER2 (CSH12)                               25-50 [b](#TFN2){ref-type="table-fn"}                                  ND                                                                                 ND
  PDGFR (NIHPDGFR)                           \> 1000 [b](#TFN2){ref-type="table-fn"}                                ND                                                                                 ND
  VEGFR-2 (PAE/ KDR)                         \> 10,000                                                              ND                                                                                 ND
  c-Src                                      ND                                                                     118 ± 26                                                                           
  IGF-1R                                     ND                                                                     \> 15,000                                                                          

The median inhibitory concentrations (IC50) values were obtained from at least three independent experiments. Where applicable, results are presented as mean ± SD.

Studies investigating the inhibitory potency toward the EGFR and related tyrosine kinases were carried out using either intact cells or a cell free kinase assay. ND: not determined.

###### 

Biodistribution of \[^18^F\]-ML04 3 h Post Administration to U87MG.wt EGFR Tumor-Bearing Mice

  Tissue               Percent of Injected Dose Per Gram of Organ (n=12)   Tumor: Tissue Activity Uptake Ratios (n=10)
  -------------------- --------------------------------------------------- ---------------------------------------------
  Blood                0.17 ± 0.02                                         7.07 ± 1.11
  Bone                 0.40 ± 0.05                                         2.42 ± 0.12
  Heart                0.33 ± 0.02                                         3.07 ± 0.20
  Intestine            2.19 ± 0.14                                         0.46 ± 0.03
  Kidneys              3.98 ± 0.25                                         0.25 ± 0.02
  Liver                1.63 ± 0.09                                         0.59 ± 0.02
  Lungs                6.11 ± 0.50                                         0.16 ± 0.01
  Muscle               0.17 ± 0.03                                         6.07 ± 0.70
  Skin                 0.59 ± 0.04                                         1.62 ± 0.05
  Spleen               2.70 ± 0.19                                         0.37 ± 0.02
  Stomach              0.94 ± 0.09                                         1.13 ± 0.09
  U87MG.wtEGFR tumor   0.99 ± 0.05                                         
